Pharm Final Flashcards
Adjuvant
tx when there is no measurable dz to suppress secondary tumor formation. Generally a treatment after surgical resection
Neoadjuvant
treatment to shrink or pre-treat tumor prior to sx
different goals for cancer tx
Cure, Remission, Palliation (reduce pain, improve fx),
Multi drug chemo protocols
standard for curative intent, or intense tx
Ideally drug combos have complimentary activity and don’t have overlapping toxicity
MTD (max tolerated dose)
dose that allows for the highest exposure (aka max pharm response/efficiacy) w/ acceptable toxicity
DLT (dose limiting toxicity)
MTD is determined by highest dose level at which no more than 1/6 patients develop a DLT
CR (complete remission) measurement response
complete disappearance of tumor and symptoms of dz
PR (partial remission) measurement response
decreased volume by > or = 50% or max diam > or = to 30%
SD (stable disease) measurement response
no increase of decrease (or increased <20% in diam)
PD (progressive dz) measurement response
increase volume >25%, increase diam >20% new lesions
Methods of resistance to chemo drugs
- decrease drug uptake
- decrease biotransformation/activation
- increase inactivation
- Multidrug resistance: ABCB-1 gene & p glycoprotein transporter
Glucocorticoids MOA
alter gene transcription
direct lytic effect on malignant cells in lymphoid malignancies, leukemia, myeloma
Antimetabolites MOA
block purine/pyrimidine biosynth (so no DNA made)
Methotrexate
folate analog
rarely used in vet med b/c enterohepatic recycling + GI accum = toxicity before therapeutic effect
5-Fluorouracil
treat epithelial tumors
Contraindicated in cats - deficient in DPD to metabolize this drug –> drug accum = toxicity
Cytosine Arabinoside, Ara-C, Cytarabine
Used for dz w/ CNS involvement because can cross BBB
Alkylating agents MOA
Interfere w/ replication
Cross link DNA by covalently binding macromolecs - no longer separatable for replication
or cause non-repairable DNA lesion
Common side effects from alkylating agents
BAG: bone marrow suppression, alopecia, GI
Cyclophosphamide
- must be metabolized in the liver to be active (drug alone won’t kill tumors) - PRO drug
- Causes SHC (sterile hemorrhagic cystitis), neutropenia, thrombocytopenia, GI side effects in cats
Chlorambucil
- use if Cyclophosphamide causes SHC or for certain chronic tumors
- delayed onset, may cause cerebellar toxicity
Chemo drugs able to cross BBB
Cytidine analogs
CCNU
Decrease occurrence of SHC
Caused by acrolein metabolite - damage bladder tissue
Mesna - neutralizes acrolein in bladder
Furosemide - diuretic dilutes & increases acrolein clearance
Also, switch to Chlorambucil
Anti-tubulin agents MOA
Interfere w/ spindle fiber formation, thus chrom separation during mitosis
stop replicating cells in M phase –> then they die
Vinca Alkaloids
inhibit microtubule assembly
- Vinchristine = peripheral neuropathy but minimal myelosuppression, for lymphoma
- Vinblastine - BAG, less neurotoxicity, for mast cell tumors
Anti-tumor antibiotics MOA
form complexes w/ DNA, inhibit DNA/RNA synth
BAG side effects
Single most broadly used chemotherapeutic active agent used in veterinary oncology
Doxorubicin. very efficaious!!
Doxorubicin MOA
inhibits RNA, DNA polymerase, topoisomaerase II
Doxorubicin toxicity
- GI, hematopoietic and cardiac toxicity
- Cardiac in dogs, renal in cats
- Cardiac related to total lifetime dose, but can also get acute toxicity, messes w/ heart through multiple mechs
- Vesicant - bad local tissue damage if leaves vessels
Mitoxantrone
synthetic doxorubicin
similar MOA but forms less ROS’s
used in dogs w/ cardiac issues or that have reached lifetime doxo limit
L-Asparaginase MOA
depletes asparaginase in blood –> inhibits protein synth in tumor cells
L-Asparaginase
- Exclusively used for lymphoproliferative disorders often in relapse settings (e.g. lymphoma)
- blocks methotrexate efficacy & toxicity
- long half life
- can get anaphylaxis, pancreatitis, DIC
Cisplatin
contraindicated in cats - fatal fulminant pulmonary edema
renal toxicity, BAGS, neurotox, ototox,
Carboplatin
BAGs, neurotox, rare nephrotoxicity
Dose based on renal fx (GFR) not weight
Molecular target agent vs. Cytotoxic agents
MTA’s block signaling pathways for tumor cell proliferation, survival
Mostly targeted toward kinase reactions (used in cell signaling ubiquitously)
Pro - only target tumors, not local tissue (vs. cytotoxic target any dividing cells)
Toceranib
TKI
Inhibits c-Kit - expressed by mast cell tumors to block formation in dogs
- resistance to drug happens quickly
- GI toxicity, neutropenia
Chemo agents that cross-link DNA
Platinum agents
alkylating agents
only 2 vet-approved chemo drugs
Palladia & Tanovea
Drugs to not give to cats
5-fluoricil
cisplat
4 ways antimicrobial drugs are classified
- class of microorganism they show activity against
- antibacterial spectrum of activity
- bacteriostatic or cidal
- time of conc dependent activity
broad spec means it potentially works against:
bacteria (G+,G-, aerobic, anaerobic), mycoplasma (no cell wall), rickettsia & chlamydia (intracellular), protozoa (euk)
What antibacterials are always static at all concentrations?
Tetracyclines
Sulfonamides
Concentration dependent drugs
higher the conc of a drug above MIC = faster rate of killing (steady state not important)
peak of Cmax (max serum conc achieved)
To optimize: give higher doses less frequently
aminoglycosides, metronidazole
Concentration and time dependent drugs
AUC (unbound drug at steady state)
fluoroquinolones
Time dependent drugs
the longer a drug maintains serums conc’s exceeding MIC, the more efficacious (higher doses don’t improve this)
T>MIC
To optimize: give lower doses more frequently
beta lactams, some macrolides, tetracyclines, TMS, chloramphenicol
MIC (minimum inhibitory conc)
lowest concentration of a drug required to inhibit visible growth of bacteria
Breakpoint MIC
value where plasma conc unlikely to be achieved, no clinical benefit against bacteria w/ MIC above that breakpoint
4 indications for use of antimicrobial combos
- antimicrobial synergism
- polymicrobial infections
- decrease chance of resistant isolates emerging
- decrease dose-related toxicity
Fluoroquinolone & Quinolone PK’s
- good oral bioavailability in monogastrics
- large vol of distribution, even to CNS, eye
- accum in macrophages, neuts, urine
- extended half-life, dose every 1-2 days
Enrofloxacin
can often metabolize into cirprofloxacin (lower MIC than enro)
Quinolone characteristics
- Extended spec (limited against strep, obligate anaerobes)
- Good against G-‘s, variable against G+
- anaerobes mostly resistant
- efficacy is concentration dependent
Quinolone MOA
Inhibit bacterial DNA gyrase and/or topoisomerase IV to inhibit DNA replication
Fluoroquinolone characteristics
- active against bacteria, mycoplasma, rickettsia, chlamydia
- antibacterial against G+/- aerobes
Bacteriostatic at MIC, bacteriacidal at higher doses - Concentration dependent activity